Olaparib (Lynparza®) as monotherapy for the maintenance treatment of adult patients with BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. This is a sub-group of the entire licensed population.
|NCPE Assessment Process||Complete|
|Rapid Review commissioned||23/07/2019|
|Rapid Review completed||06/08/2019|
|Rapid Review Outcome||A full HTA is not recommended. The NCPE recommends that olaparib not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.